SUMMARY The antiserotonergic agent cyproheptadine was evaluated in six patients as a medication for the management of spasticity due either to spinal cord trauma or to multiple sclerosis. Oral doses of cyproheptadine were progressively increased from 6 mg to 24 mg per day. Trial periods extended from 4 to 24 months and included a placebo substitution period. Cyproheptadine was found to decrease significantly the spontaneous and elicited ankle clonus in all six patients and spontaneous spasms in five patients. Cyproheptadine decreased the EMG activity and the dynamic strength produced by the knee extensor and flexor muscles during isokinetic movements in two of the four patients evaluated objectively. Subjectively, however, the patients did not report diminished strength.
the modulation of spinal reflexes has been suggested from the results of biochemical, histochemical and physiological studies. '`In a recent series of animal experiments we have demonstrated a progressive increase in sensitivity to exogenously administered 5-hydroxytryptophan (5-HTP), the precursor of 5-HT, after spinal cord transection. In these animals, cyproheptadine, a serotonergic antagonist, completely blocked the facilitatory effect of 5-HTP on spontaneous EMG activity.57 Since these results suggested a possible role of cyproheptadine in the control of spasticity in man, a pilot study was undertaken.
Patients and methods
The effect of cyproheptadine as an antispastic agent was evaluated with informed consent in six patients (five men and one woman to a traumatic lesion of the spinal cord or multiple sclerosis. In the latter cases, we could not rule out lesions elsewhere in the central nervous system, although lesions of the descending spinal pathways appeared to play a major role in the motor dysfunction. We were especially interested in patients who suffered from frequent spontaneous episodes of clonus or from massive spasms in the lower extremities.
Cyproheptadine was administered orally with an initial dosage of 12 mg/day and gradually increased to a maximum of 24 mg/day. The duration of the therapy varied from 4 to 24 months. In four of the patients, cyproheptadine was substituted by a placebo for a few days during the first month of therapy. One patient was kept on dantrolene sodium, 300 mg daily and another on baclofen 70 mg daily. 
